Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 Vaccine Plus Anti-PD-1/PD-L1 in First-Line Advanced NSCLC
2022-502437-25-00Phase 2Completed
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Aug 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of UV1 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Vestre Viken Hospital Trust. Primary endpoint: Progression-free survival. Started Aug 2023; status: completed.
02
Drugs
UV1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502437-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502437-25-00.